Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SIBIA Neurosciences (SIBI) -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (374)	5/27/1999 1:07:00 AM
From: Mike McFarland	Read Replies (2) \| Respond to of 579

<what the pain program is all about> Ah, I see Rick already pasted some stuff over in post #330. And there is a little here sibia.com Under the terms of the agreement between SIBIA and Lilly, which was completed in October of 1997, the parties will independently pursue discovery and development of drug leads that act on VGCC drug targets identified under the collaboration with SIBIA. Lilly is obligated to make milestone and royalty payments to SIBIA on compounds it identifies within a certain period of time and commercializes. Hey, regarding that OMEGA-conotoxin MVIIA--who is the third party? (NXCO I guess, so now Elan) And here are a couple links to park; grimwade.biochem.unimelb.edu.au grimwade.biochem.unimelb.edu.au Pump into spinal fluid--hmmm, maybe that third party should see CytoTherapeutics, my CTII could use a spark.